Cradle — Funding & Company Data

Cradle's funding trajectory demonstrates a rapid and confident scaling path. The company progressed from a $5.4M Seed round in late 2022 to a $24M Series A just a year later, and then a substantial $73M Series B in late 2024. This accelerated fundraising timeline, with consistent participation from early backers like Index Ventures and Kindred Capital, indicates that the company is hitting key milestones and demonstrating significant technological and commercial traction. The addition of a lead investor like IVP for the Series B round further validates their position in the market and provides a strong seal of approval.

The capital raised, now totaling over $100M, provides a significant war chest. This allows Cradle to aggressively invest in its core R&D, expand its proprietary wet lab operations to generate more training data for its AI models, and scale its go-to-market teams. For a company in the computationally and biologically intensive field of protein design, this level of funding is critical for maintaining a competitive edge. It suggests a long runway, likely several years, allowing the company to focus on product development and customer acquisition without immediate financial pressure.

From a competitive standpoint, this funding positions Cradle as a formidable player in the AI-for-biology space. While other companies are also applying AI to drug discovery and materials science, Cradle's focused platform approach, which serves a range of partners from pharmaceuticals to food tech, appears to be resonating with investors. The quality of their investors and the consistent up-rounds suggest that Cradle is executing effectively on its vision to become a core enabling technology for the broader biotechnology industry.